ArticleDiabetes care2014
Insulin analogs--is there a compelling case to use them? No!
Article in Diabetes care, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 2 syntheses or guidelines pooled it, 49 citations in OpenAlex.
- Short-acting insulin analogues versus regular human insulin for adult, non-pregnant persons with type 2 diabetes mellitus.The Cochrane database of systematic reviews · 2018Pooled it
- Short-acting insulin analogues versus regular human insulin for adults with type 1 diabetes mellitus.The Cochrane database of systematic reviews · 2016Pooled it
- A randomized pharmacokinetic and pharmacodynamic trial of two regular human insulins demonstrates bioequivalence in type 1 diabetes and availability of biosimilar insulin may improve access to this medication.Diabetes, obesity & metabolism · 2022Trial
- Basal insulin peglispro versus insulin glargine in insulin-naïve type 2 diabetes: IMAGINE 2 randomized trial.Diabetes, obesity & metabolism · 2016Trial
- From medicine price control to deregulation: assessing policy effects on insulin access in Pakistan's private pharmacies.PloS one · 2026Article
- Human Insulin as an Antidote to the High Cost of Insulin: Clinical Insignificance of Pharmacokinetic/Pharmacodynamic Differences.Clinical diabetes : a publication of the American Diabetes Association · 2023Article
- Proteomic Changes to the Updated Discovery of Engineered Insulin and Its Analogs: Pros and Cons.Current issues in molecular biology · 2022Review
- A Conversation on an Effective, Straightforward, Quantitative Approach to the Outpatient Use of Insulin.Diabetes spectrum : a publication of the American Diabetes Association · 2022Article
- 100 years of Insulin: Why is Insulin So Expensive and What Can be Done to Control Its Cost?Endocrinology and metabolism clinics of North America · 2021Review
- Cost-effectiveness of long-acting insulin analogues vs intermediate/long-acting human insulin for type 1 diabetes: A population-based cohort followed over 10 years.British journal of clinical pharmacology · 2020Article
- Realizing a Closed-Loop (Artificial Pancreas) System for the Treatment of Type 1 Diabetes.Endocrine reviews · 2019Review
- Human Insulin Versus Insulin Analogues: A True Companion Forgotten.International journal of endocrinology and metabolism · 2019Article
- Challenges constraining availability and affordability of insulin in Bengaluru region (Karnataka, India): evidence from a mixed-methods study.Journal of pharmaceutical policy and practice · 2019Article
- Advances in Care for Insulin-Requiring Patients Without Closed Loop.Diabetes technology & therapeutics · 2018Article
- Recent Updates on Type 1 Diabetes Mellitus Management for Clinicians.Diabetes & metabolism journal · 2018Review
- Efficacy, Safety, and Quality of Treatment Satisfaction of Premixed Human and Analogue Insulin Regimens in a Large Cohort of Type 2 Diabetic Patients: PROGENS BENEFIT Observational Study.International journal of endocrinology · 2018Article
- Why Are Diabetes Medications So Expensive and What Can Be Done to Control Their Cost?Current diabetes reports · 2017Review
- Ten-Year Trends in the Morbidity of Diabetes Mellitus and Antidiabetic Drug Utilization in Croatia: A Study Based on Routinely Collected Data.International journal of family medicine · 2016Article
- Status of Diabetes Care: "It just doesn't get any better . . . or does it?".Diabetes care · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
The availability of insulin analogs has offered insulin replacement strategies that are proposed to more closely mimic normal human physiology. Specifically, there are a considerable number of reports demonstrating that prandial insulin analogs (lispro, aspart, glulisine) have pharmacokinetic and pharmacodynamic profiles closer to normal, with resulting faster onset and offset of insulin effect when compared with regular human insulin. In addition, basal insulin analogs (glargine, detemir) have been reported to offer longer duration of action, less variability, more predictability, less hypoglycemia (especially nocturnal), and a favorable effect on weight. However, an argument against use of analog insulins as compared with use of regular or NPH insulin is one that states that the effectiveness and risk of hypoglycemia are the only two valid clinical outcomes that should be used to compare the analog and human insulins. Thus, there remains a debate in some circles that analog insulins are no more effective than human insulins, yet at a much higher financial cost. To provide an in-depth understanding of both sides of the argument, we provide a discussion of this topic as part of this two-part point-counterpoint narrative. In the counterpoint narrative presented here, Dr. Davidson provides his argument and defends his opinion that outside of a few exceptions, analog insulins provide no clinical benefit compared with human insulins but cost much more. In the preceding point narrative, Dr. Grunberger provides a defense of analog insulins and their value in clinical management and suggests that when evaluating the “cost” of therapy, a much more global assessment is needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.